Why the study?
Does the dosage of dalteparin affect the change in diameter and length of thrombus in patients with first symptomatic superficial vein thrombosis of the lower limbs?
Does the dosage of dalteparin affect the change in diameter and length of thrombus in patients with first symptomatic superficial vein thrombosis of the lower limbs?
The dosage of dalteparin does not appear to have a significant impact on thrombus resolution in patients with superficial vein thrombosis.
No difference in thrombus regression by dalteparin dose; leaves open optimal dosing for superficial vein thrombosis.
The aim of this study was to follow the thrombus progression and regression in superficial veins of lower limbs in patients with superficial vein thrombosis (SVT) treated with low-molecular-weight heparin. Patients (n = 68) with a first symptomatic SVT of the lower limbs received 2 different dosages of dalteparin. The primary outcome was a change in the diameter and length of thrombus in the affected veins. The regression of thrombus was not significantly different between the groups (P = .19). The reduction in the length of thrombus as well as thrombus diameter was significantly greater in females. At the end of the observation period, the length of thrombus in the distal part was more reduced than in the proximal segments. It seems that the dosage of anticoagulant drug does not have a significant impact on thrombus resolution.
No takes yet. Share an insight, caveat, or question.
Spirkoska et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: